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Abstract- Postoperative nausea and vomiting (PONV) are one of the most common complications of 
anesthesia and without prophylactic intervention occurs by about one-third of patients under general 
anesthesia. The aim of this study was to compare the efficacy of ondansetron and metoclopramide in reducing 
PONV after laparoscopic cholecystectomy. In this study, 60 patients undergoing laparoscopic 
cholecystectomy were randomly allocated into two equal groups (n=30), and in the first group 10 mg 
metoclopramide and in the second group 4 mg ondansetron preoperatively were injected. Nausea and 
vomiting and the need for rescue antiemetic treatment in recovery and 6 hr. and 6-24 hrs. After surgery were 
evaluated. Data were analyzed by SPSS software with chi-square test and analysis of variance (ANOVA). 
The incidence of nausea in metoclopramide was 43.3 % and in ondansetron was 33.3 %. The difference 
between two groups was not significant (P=0.6). The incidence of vomiting in metoclopramide was 20% and 
in ondansetron was 26.7%, and there was not any significant difference between intervention groups 
(P=0.12). For prevention of PONV after laparoscopic cholecystectomy, both metoclopramide and 
ondansetron are effective, and in preventing of nausea, ondansetron is more effective than metoclopramide, 
whereas there was not any significant difference between two drugs in preventing of vomiting.  
© 2017 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2017;55(4):254-258. 
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Introduction 
 
Postoperative nausea and vomiting (PONV) is a 
common complication of general anesthesia. PONV is 
still a clinical problem after anesthesia and surgery that 
will cause a delay in discharge from hospital (1). 
Without preventive interventions, PONV occurs in about 
one-third of patients (10-60%) under general anesthesia, 
and its complication includes wound dehiscence, 
bleeding, increased the risk of gastric contents 
aspiration, patients' delayed discharge, rehospitalisation, 
and decreased patient satisfaction. The most patients 
believe that PONV can be even more disturbing than 
postoperative pain (2). Several factors are involved in 
the etiology of PONV, so its extensive prevention is not 
cost effective. The ability to identify high-risk patients 
for preventive intervention could significantly improve 
the quality of patient care and satisfaction after surgery. 
In various studies, various factors such as female 
gender, history of motion sickness, previous history of 
PONV, nonsmoking and use of postoperative opioids 
have been reported as risk factors for PONV (1). 
Preventive interventions to reduce PONV include 
modification of anesthesia techniques and 
pharmacological intervention. Although preventive 
interventions to prevent PONV are significantly more 
effective than treatment, some patients need to be treated 
after surgery even after adequate preventive 
interventions. Both the drug categories and 
administration time are important factors to choose the 
appropriate drug for the prevention of this complication. 
In several studies, the effects of traditional medications 
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(metoclopramide, perphenazine, prochlorperazine, 
droperidol, and cyclizine) and 5-hydroxy tryptamine 
receptor antagonists (ondansetron, dolasetron, 
granisetron, and tropisetron) have been compared in 
terms of preventing PONV, and the results have been 
different and in some cases contradictory (3). From 
among these medications, metoclopramide by inhibiting 
dopamine receptors at the center of medulla oblongata 
chemoreceptor trigger zone (CTZ) reduces or inhibits 
nausea and vomiting. Ondansetron reduces the activity 
of the vagus nerve, which deactivates the vomiting 
center in the medulla oblongata, and also blocks 
serotonin receptors in the chemoreceptor trigger zone 
(4). Ondansetron is an effective drug in the prevention 
and treatment of PONV by having low side effects (5).  
Due to the minimally invasive nature and fewer 
complications, comparing with open surgery, 
laparoscopic surgery is preferable in many patients. 
Because of its less complication, laparoscopic 
cholecystectomy has been selected for treating acute 
cholecystitis. However, it has some complications such 
as PONV, and this leads us to identify a good way to 
control them (6). In addition, since the aim of 
laparoscopy is a reduction of hospitalization time, if we 
are able to control the PONV after laparoscopic 
cholecystectomy, we will be better able to achieve our 
purpose. The aim of this study was to compare the 
effects of metoclopramide and ondansetron in 
preventing PONV after laparoscopic cholecystectomy.  
  
Materials and Methods 
 
In this double-blind clinical trial study (registered at 
Iranian Registry of Clinical Trials; registration code: 
IRCT201111094093N3), after approval of the university 
ethical committee, written, informed consent to 
participate in the study was obtained from 60 patients 
who were aged 15-80 years, classified as ASA physical 
status I or II, and scheduled for elective laparoscopic 
cholecystectomy surgery. The exclusion criteria 
included gastroesophageal reflux, severe obesity, 
difficult airway management, pregnancy, breastfeeding, 
liver or kidney disease, history of opioid addiction and 
alcoholism, Body Mass Index (BMI)>30, neuromuscular 
diseases, mental diseases, diabetes, and gastrointestinal 
obstruction. Using double-blind randomization 
technique these patients were given either group M 
(metoclopramide 10 mg) or group O (ondansetron 4 
mg). 
The drugs were prepared in the same 2 cc syringes, 
and the injection was immediately before anesthesia 
induction performed by an anesthesiologist who was 
unaware of the drug kind. All patients received 1 mg of 
intravenous midazolam as premedication; the anesthetic 
induction was similarly conducted on each two groups 
by 2 μg/kg of fentanyl, 2 mg/kg of propofol and 0.5 
mg/kg of atracurium. After tracheal intubation, the 
maintenance of anesthesia was established by propofol 
infusion 100 μg/kg/min. Muscle relaxation maintained 
with injection atracurium 0.25 mg/kg with intermittent 
positive pressure ventilation to maintain ETCO2 
between 4.6-5.2 Kpa. At the cessation of the surgical 
procedure, 0.02 mg/kg atropine and 0.04 mg/kg 
neostigmine were administered by IV to reverse muscle 
relaxation, and the trachea was extubated when the 
patient was awake, and respiration was adequate and 
regular. The patients in the recovery room were 
evaluated in terms of the incidence rate of nausea and 
vomiting, a number of vomiting, the need for rescue 
antiemetic treatment, opioid pain therapy, and shivering 
incidence rate by anesthesiology assistant who was 
unaware of the type of medication prescription. In 
addition, the patients were evaluated during 6 and 6-24 
hours after surgery, in terms of the incidence of nausea, 
vomiting, and the need for rescue antiemetic treatment. 
For each case of vomiting, or nausea for more than 5 
minutes, metoclopramide 10 mg was intravenously 
injected. 
Considering 40% reduction in the incidence of 
nausea and vomiting (from 70% to 30%) in previous 
studies, and the rate of α=0.05 and β=20%, the sample 
size was calculated as the number of 30 patients per 
group. 
The collected data in previously prepared checklists 
was entered into statistical software SPSS version 18, 
analysis of variance (ANOVA) was used for comparison 
of all continuous variables between the groups. Chi-
square test was used for analysis of categorical 
demographic data. Differences were considered 
significant when P<0.05.  
 
Results 
 
The main demographic and clinical characteristics of 
the patients under investigation were not significantly 
different between the two groups (Table 1).  
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Table 1. Demographic and clinical characteristics of patients 
Variables 
Ondansetron 
(n=30) 
Metoclopramide 
(n=30) 
P 
Gender 
Male 7(23.3) 4(13.3) 
0.5 
Female 23(76.7) 26(86.7) 
Age (yr) 45.97±13.07 46.27±15.19 0.93 
Weight (kg) 72.47±7.91 69.97±8.82 0.25 
Residency 
Urban 16(53.3) 23(76.7) 
0.103 
Rural 14(46.7) 7(23.3) 
Smokers 5(16.6) 3(10) 0.71 
Duration of operation (min) 84.67±16.01 79.23±13.42 0.16 
Systolic Blood Pressure(mmHg) 128.5±10.14 132.47±11.45 0.16 
Diastolic Blood Pressure(mmHg) 77.10±7.21 81.43±9.67 0.06 
Heart Rate(beat/min) 81.33±12.82 82.20±13.17 0.8 
Data presented as mean±SD or number (%) 
 
 
The incidence of PONV and need for rescue 
antiemetic medication in the recovery room, during the 
first 6 hrs, and during 6-24 hrs after surgery is 
summarized in Table 2. 
 
Table 2. Incidence (%) of PONV and proportion (%) of patients requiring the 
antiemetic medication 
Outcome 
Ondansetron 
(n=30) 
Metoclopramide 
(n=30) 
P 
In recovery 
Nausea 1(3.3) 9(30) 0.012 
Vomiting 0(0) 1(3.3) 1 
Antiemetic medication 0(0) 6(20) 0.024 
During 6 hrs 
Nausea 7(23.3) 13(43.3) 0. 17 
Vomiting 6(20) 5(16.7) 1 
Antiemetic medication 7(23.3) 8(26.8) 1 
During 6-24 
hrs 
Nausea 3(10) 0(0) 0.24 
Vomiting 2(6.7) 0(0) 0.5 
Antiemetic medication 3(10) 0(0) 0.23 
Entire 24hrs 
Nausea 10(33.3) 13(43.3) 0.6 
Vomiting 8(26.7) 6(20) 0.7 
Antiemetic medication 10(33) 11(36) 1 
 
 
In terms of the incidence rate of nausea in the 
recovery room, we found the significant statistical 
difference between ondansetron and metoclopramide 
groups (P=0.012). The incidence of nausea during the 
first 6 hrs (P=0.17) and during 6-24 hours after surgery 
was not statistically significant between two groups 
(P=0.24). In terms of the entire 24 hrs period incidence 
of nausea, we don't saw the statistically significant 
difference between ondansetron and metoclopramide 
groups (P=0.6). 
 The incidence rate of vomiting during recovery 
room (P=1), the first 6 (P=1), 6-24 hrs after surgery 
(P=0.5) and the entire 24 hrs period was not a significant 
difference among the two groups (P=0.7).  
In terms of the need for rescue antiemetic medication 
during recovery room, there was a statistically 
significant difference between ondansetron and 
metoclopramide groups (P=0.024). However, we 
couldn’t see a statistical difference during the first 6 
(P=1) and during 6-24 hrs after surgery between two 
groups (P=0.23).  
Among the patients, 5 patients (16.7%) from 
ondansetron group, 3 patients (10%) from 
metoclopramide group had more than once vomiting 
during the first 6 hours after surgery, and the difference 
between the mentioned groups was not statistically 
significant (P=0.06). This rate in two groups during 6-24 
hrs after surgery was reduced to the first 6 hrs, and the 
number of vomiting between groups was not statistically 
different (P=0.66). 
The incidence rate of postoperative shivering was 
not a significant difference among the groups (P=0.7).  
In terms of the different factors' effect on PONV, 
smoking (P=0.03) and surgery duration greater than 90 
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minutes (P=0.01) significantly reduced the incidence of 
this complication in the two groups. However, there was 
no statistically significant difference between the 
incidence of this complication and gender and age of 
patients in different groups (P>0.05). 
 
Discussion 
 
PONV is amongst the most common complications 
following anesthesia and surgery with a selectively high 
incidence after laparoscopic cholecystectomy. The cause 
of PONV after laparoscopic cholecystectomy is complex 
and multifactorial and depends on various factors such 
as patients' demographic characteristics, type of 
anesthetic drugs and techniques, and postoperative cares 
(7,8). 
 In this clinical trial, patients were similar in terms of 
demographic variables, duration of surgery and basic 
vital signs. In the study of entire 24 hrs period incidence 
of PONV among the two groups, it was observed that 
nausea incidence rate and the incidence rate of vomiting 
in both ondansetron and metoclopramide groups wasn’t 
statistically significant.  
Many studies reported that ondansetron is 
statistically superior to metoclopramide for prevention 
of PONV (9,10,11,12). Other published studies that 
evaluated the efficacy of ondansetron and 
metoclopramide administered intravenously have shown 
similar reductions in the incidence of PONV during the 
24 h post recovery period (13,14,15). 
In a separate survey of postoperative nausea in some 
studies, as well as our study, the effect of ondansetron 
was higher than metoclopramide (12), however, in other 
studies, there was no significant difference between the 
two drugs (13). In terms of the incidence of 
postoperative vomiting, the result of our study was 
similar to some studies (13) and was different from other 
studies (12).  
In this study, the effect of smoking history on the 
incidence rate of PONV was statistically significant, and 
it had reduced this rate in two groups. This result is 
similar to results from other studies (1,16) investigating 
the risk factors for PONV. 
 In entire 24 hrs period incidence of PONV based on 
gender, this rate was higher in females although there 
were no significant differences between different 
groups. In previous studies female gender is known as 
one of the risk factors for PONV (1,17).  
In our study, the patients were studied in four 
different age groups. Although the age group above 70 
years compared to other age groups had a lower 
incidence of PONV, this difference was not statistically 
significant. Other studies also confirm high incidence of 
PONV in young people (1).  
Like most of the studies, this study had also some 
limitations including the duration of the patients’ follow-
up. If the duration of follow-up were longer, results that 
are more accurate would be obtained.  
This study shows that both ondansetron and 
metoclopramide are effective in reducing PONV after 
laparoscopic cholecystectomy. Effectiveness rate of 
ondansetron in reducing nausea is more than 
metoclopramide, but in terms of reducing postoperative 
vomiting, there was no significant difference between 
two drugs. 
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